Growing companies through in-licensing marketed products has not always been successful: such products are often pharmaceutical company cast-offs at the end of their life cycle. But CeNeS Pharmaceuticals plc, which just acquired three pain killing products from Glaxo Wellcome plc, believes having a pharmaceuticals division is a vital component in its strategy to build a specialty business in the CNS space.

CeNeS (LSE:CEN, Cambridge, U.K.) paid £10 million for rights in the U.K. and Ireland to Diclonal and Cyclicmorph, analgesics combined with anti-emetics to treat severe pain, and Valoid, an anti-emetic to treat vomiting and nausea. The company expects combined